Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BMT CTN 1102
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
- NCT02016781 ↗
- Completed
- Medical College of Wisconsin
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on BMT CTN 1102 (intermediate-2 and high-risk myelodysplastic syndrome; tests no drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BMT CTN 1102 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 10 posts on X | |
| 5 podcast episodes | |
| 2 YouTube videos |
The trial
ClinicalTrials.gov- Official title
- A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMTCTN1102)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- MDS
- Interventions
- Allogeneic Hematopoietic Cell Transplant; Hypomethylating Therapy / Best Supportive Care
- Arms
- Transplant · Active comparator
- Hypomethylating Therapy / Best Supportive Care · Active comparator
- Enrollment
- 384
- Primary outcomes
- Percentage of Participants With Overall Survival (OS)
- Sponsor
- Medical College of Wisconsin with National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program
- Start
- Dec 16, 2013
- Primary completion
- Oct 5, 2021
- Results posted
- Yes
- Registry record
- NCT02016781 · updated Mar 3, 2023
Publications
linked from the registry- Saber W, Le Rademacher J, Sekeres M, Logan B, Lewis M, Mendizabal A, Leifer E, Appelbaum FR, Horowitz MM, Nakamura R, Cutler CS. Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. Biol Blood Marrow Transplant. 2014 Oct;20(10):1566-72. doi: 10.1016/j.bbmt.2014.06.010. Epub 2014 Jun 24. PubMed 24972249
- Saber W, Bansal A, Li L, Scott BL, Sangaralingham LR, Thao V, Roth JA, Wright W, Steuten LMG, Pidala JA, Mishra A, Maziarz RT, Westervelt P, McGuirk JP, Cutler C, Nakamura R, Ramsey SD. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102. JCO Oncol Pract. 2024 Apr;20(4):572-580. doi: 10.1200/OP.23.00413. Epub 2024 Jan 23. PubMed 38261970
- Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, McGuirk J, Maziarz RT, Westervelt P, Hegde P, Mukherjee D, Martens MJ, Logan B, Horowitz M, Hourigan CS, Nakamura R, Cutler C, Lindsley RC; Blood and Marrow Transplant Clinical Trials Network. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. J Clin Oncol. 2023 Oct 1;41(28):4497-4510. doi: 10.1200/JCO.23.00866. Epub 2023 Aug 22. PubMed 37607457
- Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, Logan BR, Shaw BE, Gregory A, D'Souza A, Hamilton BK, Horowitz MM, Flynn KE. Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102. Am J Hematol. 2023 Feb;98(2):229-250. doi: 10.1002/ajh.26768. Epub 2022 Nov 21. PubMed 36251401
- Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021 Oct 20;39(30):3328-3339. doi: 10.1200/JCO.20.03380. Epub 2021 Jun 9. PubMed 34106753